NO962073L - Amfifiliske imidazoliniumderivater - Google Patents

Amfifiliske imidazoliniumderivater

Info

Publication number
NO962073L
NO962073L NO962073A NO962073A NO962073L NO 962073 L NO962073 L NO 962073L NO 962073 A NO962073 A NO 962073A NO 962073 A NO962073 A NO 962073A NO 962073 L NO962073 L NO 962073L
Authority
NO
Norway
Prior art keywords
imidazolinium derivatives
amphiphilic imidazolinium
amphiphilic
amphiphiles
derivatives
Prior art date
Application number
NO962073A
Other languages
English (en)
Other versions
NO962073D0 (no
NO305557B1 (no
Inventor
Timothy D Heath
Igor Solodin
Original Assignee
Megabios Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Megabios Corp filed Critical Megabios Corp
Publication of NO962073D0 publication Critical patent/NO962073D0/no
Publication of NO962073L publication Critical patent/NO962073L/no
Publication of NO305557B1 publication Critical patent/NO305557B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/10Phosphatides, e.g. lecithin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
NO962073A 1993-11-24 1996-05-21 Amfifiliske imidazoliniumderivater og fremgangsmÕte for fremstilling av imidazoliniumion NO305557B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15772793A 1993-11-24 1993-11-24
US08/247,963 US5705655A (en) 1992-12-17 1994-05-24 Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
PCT/US1994/013363 WO1995014380A1 (en) 1993-11-24 1994-11-17 Amphiphilic imidazolinium derivatives

Publications (3)

Publication Number Publication Date
NO962073D0 NO962073D0 (no) 1996-05-21
NO962073L true NO962073L (no) 1996-07-09
NO305557B1 NO305557B1 (no) 1999-06-21

Family

ID=26854423

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962073A NO305557B1 (no) 1993-11-24 1996-05-21 Amfifiliske imidazoliniumderivater og fremgangsmÕte for fremstilling av imidazoliniumion

Country Status (11)

Country Link
US (2) US5705655A (no)
EP (1) EP0730404B1 (no)
JP (1) JP2918693B2 (no)
KR (1) KR100246839B1 (no)
AT (1) ATE258923T1 (no)
AU (1) AU691217B2 (no)
CA (1) CA2176713C (no)
DE (1) DE69433532T2 (no)
NO (1) NO305557B1 (no)
NZ (1) NZ276645A (no)
WO (1) WO1995014380A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910487A (en) * 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5747471A (en) * 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5767099A (en) * 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US5840710A (en) * 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US6093816A (en) * 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6235310B1 (en) 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
US6121457A (en) 1997-11-14 2000-09-19 Megabios Corporation Compositions and methods using novel substituted imidazolium lipids
US9034330B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
US9034329B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
JP4799736B2 (ja) 1999-02-22 2011-10-26 ジョージタウン・ユニバーシティ 全身性遺伝子送達のための抗体フラグメント標的化イムノリポソーム
AU2002307035A1 (en) * 2001-04-02 2002-10-15 Georgetown University A simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome or polyplex for systemic administration of a therapeutic or diagnostic agent
US7297712B2 (en) * 2002-03-27 2007-11-20 Council Of Scientific And Industrial Research Cationic amphiphiles for intracellular delivery of therapeutic molecules and its composition, process and method of treatment
US8044215B2 (en) * 2009-04-29 2011-10-25 Juvaris Biotherapeutics, Inc. Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds
CA2916898A1 (en) 2013-07-16 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of osteogenic potential of bone grafts
MX393908B (es) * 2015-05-04 2025-03-24 Elanco Animal Health Gmbh Proceso mejorado para la preparacion de compuestos anfifilicos de imidazolinio.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2945821A (en) * 1956-10-24 1960-07-19 Nalco Chemical Co Process of inhibiting corrosion
US3186912A (en) * 1959-08-03 1965-06-01 Robert L Beamer Cosmetic emulsion
US3210312A (en) * 1961-07-25 1965-10-05 Geigy Chem Corp Anti-electrostatic imidazoline salts for resin compositions
NL281319A (no) * 1961-07-25
US3205092A (en) * 1962-02-20 1965-09-07 Geigy Chem Corp Magnetic tape having improved antistatic properties
US3216957A (en) * 1962-08-14 1965-11-09 Union Carbide Corp Antistatic thermoplastic vinyl resin compositions comprising oxyalkylated imidazolines
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules

Also Published As

Publication number Publication date
JPH09505594A (ja) 1997-06-03
US5705655A (en) 1998-01-06
NO962073D0 (no) 1996-05-21
US5736395A (en) 1998-04-07
DE69433532D1 (de) 2004-03-11
CA2176713A1 (en) 1995-06-01
KR100246839B1 (ko) 2000-08-01
EP0730404B1 (en) 2004-02-04
EP0730404A4 (en) 1997-02-19
NO305557B1 (no) 1999-06-21
WO1995014380A1 (en) 1995-06-01
EP0730404A1 (en) 1996-09-11
CA2176713C (en) 2000-02-22
AU1099995A (en) 1995-06-13
NZ276645A (en) 1998-05-27
ATE258923T1 (de) 2004-02-15
JP2918693B2 (ja) 1999-07-12
AU691217B2 (en) 1998-05-14
DE69433532T2 (de) 2005-01-05

Similar Documents

Publication Publication Date Title
NO962073L (no) Amfifiliske imidazoliniumderivater
ES552627A0 (es) Procedimiento para la preparacion de carbamatos de fenilo
DK0758248T3 (da) Formuleringer til faktor IX
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
NL980012I2 (nl) Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.
NO962074L (no) Amfifiliske derivater av guanidin
FI964285L (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
ES2139024T3 (es) Produccion de xilitol por recombinacion y huesped utilizado para este procedimiento.
MX9702666A (es) Nuevos peptidos con efectos inmunoreguladores.
MX9302116A (es) Compuestos azabiciclo.
MY120683A (en) New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals.
ES2174113T3 (es) Nuevos derivados de ((3-alcoxi-fenoxi)-etil)-dialquilamina y su utilizacion como anestesicos locales.
BG40803A3 (bg) Метод за получаване на арилциклобутилалкиламинови производни
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
FI953506L (fi) Monia lääkeaineita vastaan vastustuskykyisten kasvainten lääkkeinä käyttökelpoiset diaryylialkyylipiperidiinit
ATE227122T1 (de) Stabilisierte tablettenformulierung
BG40143A3 (en) Method for preparing acetamide derivatives
FR2622104B1 (fr) Procede de stabilisation de phases lamellaires lipidiques hydratees, par ex. de liposomes, composition de phases lamellaires lipidiques hydratees, par ex. des liposomes, stabilisees par un emploi d'un support stabilisant a base d'atelocollagene et de glycosaminoglycannes et utilisation en pharmacie ou en cosmetologie
ES8402819A1 (es) Procedimiento para la produccion de una 3,3-dialquil-o 3,3-dialquileno-indolina.
KR970006264A (ko) 신규한 6-치환-5, 8-디옥시-1, 4-나프토퀴논 유도체, 그의 제조방법 및 그의 항암제로서의 용도
MX9206365A (es) Tetrahidrobenzotienopiridinas,proceso para su preparacion y composicion farmaceutica que las contiene
IT8021160A0 (it) Apparecchio per la somministrazione di gas.
FI945414A0 (fi) Menetelmä N,N-disubstituoidun aminofenolin valmistamiseksi
ES474052A1 (es) Procedimiento para la obtencion de 1,4-dihidropiridazinas 1-n-sustituidas.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN MAY 2003